Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.

Proteomics is a systematic approach for studying the identity and function of all proteins expressed in a cell, tissue or organ. New drug targets for diseases are often identified by comparing the proteome of the disease state to the normal state. As a result, proteomics has become increasingly important in the pharmaceutical and biotechnology industries as well as academics. This book contains five sections encompassing the research aspects of proteomics on the brain including the most recent advances in the technology and informatics. It discusses advances in high-throughput proteomic technologies and their application to studying neurological disorders such as Alzheimer's disease, alcoholism, trauma/stroke, Huntington's disease, and Parkinson's disease. With numerous illustrations to explain the concepts, it provides a comprehensive review on the topic.* Describes the latest databases and techniques for analyzing the data generated by proteomics* Outlines the latest developments in proteomic methods* Provides numerous color illustrations highlighting the application of proteomics to the identification of novel drug targets and biomarkers

It is increasingly recognized that various transporter proteins are expressed throughout the body and determine absorption, tissue distribution, biliary and renal elimination of endogenous compounds and drugs and drug effects. This book will give an overview on the transporter families which are most important for drug therapy. Most chapters will focus on one transporter family highlighting tissue expression, substrates, inhibitors, knock-out mouse models and clinical studies.

PROVIDES STRATEGIES AND CONCEPTS FOR UNDERSTANDING CHEMICAL PROTEOMICS, AND ANALYZING PROTEIN FUNCTIONS, MODIFICATIONS, AND INTERACTIONS—EMPHASIZING MASS SPECTROMETRY THROUGHOUT Covering mass spectrometry for chemical proteomics, this book helps readers understand analytical strategies behind protein functions, their modifications and interactions, and applications in drug discovery. It provides a basic overview and presents concepts in chemical proteomics through three angles: Strategies, Technical Advances, and Applications. Chapters cover those many technical advances and applications in drug discovery, from target identification to validation and potential treatments. The first section of Mass Spectrometry-Based Chemical Proteomics starts by reviewing basic methods and recent advances in mass spectrometry for proteomics, including shotgun proteomics, quantitative proteomics, and data analyses. The next section covers a variety of techniques and strategies coupling chemical probes to MS-based proteomics to provide functional insights into the proteome. In the last section, it focuses on using chemical strategies to study protein post-translational modifications and high-order structures. Summarizes chemical proteomics, up-to-date concepts, analysis, and target validation Covers fundamentals and strategies, including the profiling of enzyme activities and protein-drug interactions Explains technical advances in the field and describes on shotgun proteomics, quantitative proteomics, and corresponding methods of software and database usage for proteomics Includes a wide variety of applications in drug discovery, from kinase inhibitors and intracellular drug targets to the chemoproteomics analysis of natural products Addresses an important tool in small molecule drug discovery, appealing to both academia and the pharmaceutical industry Mass Spectrometry-Based Chemical Proteomics is an excellent source of information for readers in both academia and industry in a variety of fields, including pharmaceutical sciences, drug discovery, molecular biology, bioinformatics, and analytical sciences.

The nature of cancer disease, its probable causes, and the molecular and cellular mechanisms through which malignant tumours develop, have only recently begun to be understood in any appreciable detail. Cancer is fundamentally a disease of the genome, arising from dynamic changes occurring within DNA during the lifetime of the cell e.g. deletions, amplifications, point mutations, translocations, that can occur in any cell and that may interact in a variety of cellular pathways. The imbalance in the interplay between genetic and environmental factors can initiate malignancy. The determination of the human genome sequence is acclaimed as one of the great achievements made possible by the rapid progress in the available molecular biology tools achieved during the last few years. The sequence of the human genome promises to unveil invaluable information useful for the development of novel approaches in the diagnosis and treatment of cancer disease. This book includes part of the work of international experts on the most up-to-date developments of various aspects of research on genome and proteome in oncology. The scientists suggest that the genetic key to human complexity lies not in the number of genes but in how gene parts are used to build different products in a process of the mRNA transcript called alternative splicing.

Presenting comprehensive, cutting-edge information on the science of oncology and the multimodality treatment of every cancer type, this eighth edition--now in full color--contains more than 40 brand-new chapters, and more than 70 chapters have been rewritten by new contributing authors.